For psilocybin, 5-MeO-DMT, LSD and MDMA, clinical trials are the only legal route in most of Europe — and they are a better route than their reputation suggests: free, closely supervised, and governed by participant rights that commercial care rarely matches. The catch is on the way in: criteria are strict, screening is thorough, and most applicants do not get through. Knowing that in advance saves a lot of disappointment. If you also need care now, keep an approved option moving with your clinician in parallel — start with our eligibility check.
TL;DR Trials are free, voluntary and ethics-committee supervised. You may receive a placebo, and you can withdraw at any time without losing your regular care. Most applicants are screened out — that is normal and not a judgment on you. Active sponsors with European sites in 2026: Compass Pathways (psilocybin, Phase 3), atai/Beckley (BPL-003, sites in Germany, Poland, Spain and the UK), GH Research (around 20 sites in seven countries), and MindMed. Search ClinicalTrials.gov and euclinicaltrials.eu.
At a glance
| What it is | Enrolling in a supervised, ethics-approved study of an investigational psychedelic or ketamine treatment |
| Legal status | Legal across the EU/EEA, UK and Switzerland; for psilocybin, LSD, MDMA and 5-MeO-DMT this is usually the only lawful route |
| Who qualifies | Study-specific inclusion/exclusion criteria — often a documented diagnosis with a set number of failed treatments; most applicants are screened out |
| Cost range | Free — the investigational treatment and study procedures cost you nothing; travel is commonly reimbursed |
| How to start | Search ClinicalTrials.gov and euclinicaltrials.eu (CTIS), complete a pre-screening, then attend a site screening visit |
How a trial actually works
Trials test an investigational treatment in stages: Phase 1 checks safety and dosing, usually in healthy volunteers; Phase 2 tests whether it works in patients; Phase 3 confirms efficacy in larger groups before a marketing application. Most psychedelic programs recruiting European patients in 2026 are in Phase 2 or 3.
Two design features surprise first-time participants:
- Randomization and placebo control. You are assigned by chance to the active dose or a comparator — a placebo or a very low dose of the same compound. Neither you nor (in blinded trials) the study team chooses. Some studies offer the active treatment later in an open-label extension, but this is never guaranteed.
- Informed consent. Before any procedure you receive a written document covering the study's purpose, risks, alternatives and your rights, and discuss it with the team. Signing is not a contract to finish — you can withdraw at any time, without giving a reason, without losing your standard care.
The screening funnel — and why failing it is normal
Every trial has inclusion and exclusion criteria: a specific diagnosis (often treatment-resistant depression with a documented number of failed antidepressants), age limits, and a long exclusion list — commonly a personal or family history of psychosis or bipolar disorder, significant cardiovascular disease, recent suicide attempts, certain medications (many trials require supervised tapering of serotonergic antidepressants), pregnancy, and recent psychedelic use.
The funnel usually runs: an online or phone pre-screening covering the headline criteria, then a full site screening visit — medical history, psychiatric interviews, blood tests, ECG. Screen failure is the norm, not the exception. The criteria protect participants and keep the science interpretable; being screened out usually means the trial cannot safely or cleanly include your profile, and a detail that excludes you from one study may be acceptable in another.
What to expect in a dosing study
If you are enrolled, a psychedelic study is more involved than a single appointment, and it helps to picture the arc. After the screening visit and consent, most protocols include one or more preparation sessions with the study therapists to build rapport and set expectations. On a dosing day you take the investigational compound in a calm, monitored room, usually with two staff present for many hours; your blood pressure and heart rate are checked regularly, and the acute experience can involve marked perceptual and emotional changes, transient anxiety, nausea or a temporary rise in blood pressure. You stay until the effects have clearly subsided and you are stable, and you will not drive that day, so travel is arranged in advance.
Dosing is followed by integration sessions to help make sense of the experience, and then a schedule of follow-up visits with questionnaires that can run for weeks or months. Ketamine and esketamine studies tend to look more medical — shorter monitored sessions, often without any antidepressant taper — while psilocybin, LSD, MDMA and 5-MeO-DMT studies lean on the fuller prepare-dose-integrate model. Throughout, the study team, an independent ethics committee and the national regulator are watching for your safety.
Risks and who should not join
A trial is supervised, but the compounds still carry real effects, and the exclusion criteria exist to keep participants safe. Common transient effects on a dosing day include intense perceptual and emotional shifts, anxiety, nausea, and a short-lived rise in blood pressure and heart rate. Studies routinely exclude, or require careful specialist evaluation for, people with:
- Significant cardiovascular disease, uncontrolled hypertension or aneurysmal vascular disease, because of the cardiovascular load during dosing.
- A personal or family history of psychosis or bipolar disorder, given the risk of destabilisation with classic psychedelics.
- Pregnancy or breastfeeding.
- Recent suicide attempts or acute instability, and certain concurrent medications (which is why some trials require a supervised antidepressant taper).
None of this is a reason to avoid trials — it is the reason they are safe. If a study excludes you, ask the site what specifically ruled you out and whether another protocol might fit.
Who is recruiting in Europe in 2026
| Sponsor | Compound | Condition | European footprint |
|---|---|---|---|
| Compass Pathways | COMP360 (synthetic psilocybin) | Treatment-resistant depression | Phase 3 program, sites in several countries |
| atai Life Sciences / Beckley Psytech | BPL-003 (intranasal 5-MeO-DMT) | Treatment-resistant depression | Sites in Germany, Poland, Spain, UK |
| GH Research | GH001 (inhaled 5-MeO-DMT) | Treatment-resistant depression | ~20 sites across ~7 countries |
| MindMed | MM120 (LSD) | Generalized anxiety disorder, depression | US-centered pivotal program; check registries for EU sites |
Academic programs that regularly recruit include University Hospital Basel, the Central Institute of Mental Health (ZI) Mannheim, Imperial College London, King's College London, Maastricht University, the NRU in Copenhagen, and NUDZ near Prague. Dedicated research sites such as Clerkenwell Health in London run studies for multiple sponsors.
Where to look
- ClinicalTrials.gov — the largest registry; filter by condition, intervention, recruitment status and country.
- euclinicaltrials.eu (CTIS) — the EU's official Clinical Trials Information System.
- Sponsor and university sites often list recruiting locations and pre-screening forms directly.
Listings lag reality: a study marked "recruiting" may have site-level waiting lists or paused enrollment. Contact the site.
Your rights, and what it costs
Participation in an EU/EEA, UK or Swiss trial means no cost to you for the investigational treatment and study procedures — travel reimbursement is common; the right to withdraw at any time without penalty; oversight by an independent ethics committee and the national medicines regulator; mandatory insurance covering study-related harm; and GDPR-level data protection. What it costs you is time and commitment: often months of visits, questionnaires and follow-up. If you need care now, pursue approved options with your clinician in parallel with any trial application — and if funding rather than legality is your barrier, see the Europe-wide reimbursement map for what your country covers.
Frequently asked questions
Do I have to pay to join a trial?
No. Treatment and procedures are free, and travel is commonly reimbursed. Anyone charging a fee for "trial access" is defrauding you.
Can I choose to get the real drug instead of placebo?
No — assignment is randomized. Some protocols include open-label extensions where all participants eventually receive the active compound; ask about this during consent.
I was rejected at screening. Am I out permanently?
Not necessarily. Criteria differ between studies; ask the site what excluded you and whether another study or later re-screening might fit.
Will I have to stop my antidepressants?
Many psychedelic trials require tapering serotonergic medication under supervision, but not all — esketamine and some ketamine studies keep you on your oral antidepressant. This is a key question for the pre-screening call, and any taper decision belongs to you and your prescriber.
How long does a dosing day take, and can I drive afterwards?
Dosing days are long — often the better part of a day under monitoring until the effects subside. You will not be able to drive afterwards, so the site will expect you to arrange transport home.
What are the common side effects during dosing?
Expect marked but temporary perceptual and emotional changes, and sometimes anxiety, nausea, or a short rise in blood pressure and heart rate. Staff monitor throughout, and effects resolve as the compound clears.
Sources
- ClinicalTrials.gov
- EU Clinical Trials Information System (CTIS)
- Compass Pathways: Phase 3 COMP360 results announcement
- atai Life Sciences: pipeline
- GH Research: clinical programs
- MindMed: pipeline
- Clerkenwell Health
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Trial availability, criteria and site lists change frequently; always verify current details on the official registries and discuss participation with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.